Drugs / DC/MM fusion vaccine
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06799026 | Jan 2025 → Sep 2028 expected | plasma cell myeloma | David Avigan | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DC/MM fusion vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06799026 ↗ |
| Modality | Vaccine | “a personalized cancer vaccine” NCT06799026 ↗ |
| Route | Subcutaneous | “via subcutaneous (under the skin) injection per protocol” NCT06799026 ↗ |